MY207540A - Crystal of pyrimidine compound - Google Patents

Crystal of pyrimidine compound

Info

Publication number
MY207540A
MY207540A MYPI2023000055A MYPI2023000055A MY207540A MY 207540 A MY207540 A MY 207540A MY PI2023000055 A MYPI2023000055 A MY PI2023000055A MY PI2023000055 A MYPI2023000055 A MY PI2023000055A MY 207540 A MY207540 A MY 207540A
Authority
MY
Malaysia
Prior art keywords
crystal
compound
powder
type
characteristic peaks
Prior art date
Application number
MYPI2023000055A
Other languages
English (en)
Inventor
Takahiro Asai
Hiroyuki Nakamura
Hiroyoshi Yamanaka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MY207540A publication Critical patent/MY207540A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
MYPI2023000055A 2020-07-15 2021-07-14 Crystal of pyrimidine compound MY207540A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020121520 2020-07-15
PCT/JP2021/026460 WO2022014638A1 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Publications (1)

Publication Number Publication Date
MY207540A true MY207540A (en) 2025-03-04

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2023000055A MY207540A (en) 2020-07-15 2021-07-14 Crystal of pyrimidine compound

Country Status (12)

Country Link
US (1) US12492208B2 (cg-RX-API-DMAC7.html)
EP (1) EP4183788A4 (cg-RX-API-DMAC7.html)
JP (1) JP7391226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102914926B1 (cg-RX-API-DMAC7.html)
CN (1) CN116249534B (cg-RX-API-DMAC7.html)
AU (1) AU2021307245B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000765A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000692A (cg-RX-API-DMAC7.html)
MY (1) MY207540A (cg-RX-API-DMAC7.html)
PH (1) PH12023550116A1 (cg-RX-API-DMAC7.html)
TW (1) TWI905228B (cg-RX-API-DMAC7.html)
WO (1) WO2022014638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
TWI605049B (zh) * 2015-01-30 2017-11-11 Taiho Pharmaceutical Co Ltd Novel salts of condensed pyrimidine compounds and their crystallization
SG11201708793SA (en) * 2015-05-12 2017-11-29 Taiho Pharmaceutical Co Ltd Crystals of azabicyclic compound
KR102075886B1 (ko) 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
JP7223684B2 (ja) * 2017-02-28 2023-02-16 大鵬薬品工業株式会社 ピラゾロ[3,4-d]ピリミジン化合物を用いた抗腫瘍効果増強剤
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
TWI769395B (zh) 2018-08-29 2022-07-01 日商大鵬藥品工業股份有限公司 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
PL3909584T3 (pl) 2019-01-11 2024-03-25 Taiho Pharmaceutical Co., Ltd. Związek pirymidynowy lub jego sól
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
KR102873219B1 (ko) * 2020-07-15 2025-10-17 다이호야쿠힌고교 가부시키가이샤 Egfr 저해제

Also Published As

Publication number Publication date
PH12023550116A1 (en) 2024-06-24
KR20230034341A (ko) 2023-03-09
CA3189457A1 (en) 2022-01-20
MX2023000692A (es) 2023-02-13
TWI905228B (zh) 2025-11-21
AU2021307245A1 (en) 2023-03-02
JP7391226B2 (ja) 2023-12-04
US20230331730A1 (en) 2023-10-19
AU2021307245B2 (en) 2024-02-29
TW202216717A (zh) 2022-05-01
EP4183788A4 (en) 2024-07-17
US12492208B2 (en) 2025-12-09
WO2022014638A1 (ja) 2022-01-20
CN116249534B (zh) 2025-03-25
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
KR102914926B1 (ko) 2026-01-19
JPWO2022014638A1 (cg-RX-API-DMAC7.html) 2022-01-20
BR112023000765A2 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CA2397450A1 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
IL275762B2 (en) History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
SE0202463D0 (sv) Novel compounds
GEP20247655B (en) Crystalline salt forms of kinase inhibitor
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
NZ602710A (en) Use of novel pan-cdk inhibitors for treating tumors
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12023550116A1 (en) Crystal of pyrimidine compound
NZ601635A (en) Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.
CR20230479A (es) Formas de sales y sólidas de un inhibidor de cinasas
EA202192903A1 (ru) Кристаллическая форма ингибитора plk4
MX2025001201A (es) Sales y cristales novedosos
MY200551A (en) The salts of a compound and the crystalline forms thereof
PH12020551736A1 (en) The crystalline forms of a compound
EP4327814A3 (en) Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2022004274A (es) Las sales de un compuesto y sus formas cristalinas.
RU2014129416A (ru) Композиции, синтез и способы применения производных фенилциклоалкилметиламина